Retinopathy of Prematurity and Intravitreal Bevacizumab Treatment: Single Center Experience Prematüre Retinopatisi ve İntravitreal Bevacizumab Tedavisi: Tek Merkez Deneyimi

Creative Commons License

Dorum B. A., Şenocak Z., Yaşar M., Demirağ D.

Journal of Uludag University Medical Faculty, cilt.49, sa.1, ss.17-21, 2023 (Scopus, TRDizin)

Özet

In this study, the frequency of retinopathy of prematurity (ROP) in premature infants born in a tertiary state hospital, and the characteristics of infants with ROP and requiring treatment were investigated. In addition, experiences regarding the treatment and follow-up processes applied for RROP were shared. In the study, the data of premature babies born before 35 weeks were analyzed retrospectively. The data of infants with and without treatment indication among infants who developed ROP were compared. In the study, the data of 112 infants who were treated in our unit over two years and followed up for ROP were evaluated. The mean gestational age of the babies was 28.37±2.55 weeks, and the mean birth weight was 1171.66±405.17 grams. ROP was detected in 44 (39.2%) of the babies. Among infants who developed ROP, those who received treatment indication (n: 10) were infants with lower birth weight and higher inotrope requirement (p<0.05). ROP was not detected in premature babies born at 30 weeks or more. The highest birth week of babies who developed severe ROP was 27. As a treatment, intravitreal bevacizumab injection was successfully applied. The age of detection of ROP is advancing towards lower weeks in our country. Intravitreal bevacizumab is an effective and short-term safe treatment method that can be applied at the bedside.